temozolomide


Also found in: Wikipedia.

temozolomide

 [tem″ah-zo´lah-mīd]
a cytotoxic alkylating agent used as an antineoplastic in the treatment of refractory anaplastic astrocytoma, administered orally.

temozolomide

/tem·o·zo·lo·mide/ (tem″ah-zo´lah-mīd) a cytotoxic alkylating agent used as an antineoplastic in the treatment of refractory anaplastic astrocytoma.

temozolomide

a miscellaneous antineoplastic agent.
indication It is used to treat anaplastic astrocytoma with relapse.
contraindications Pregnancy, lactation, and known hypersensitivity to this drug or to carbazine prohibit its use.
adverse effects Life-threatening effects are thrombocytopenia, leukopenia, and seizures. Other adverse effects include anemia, urinary incontinence, urinary tract infection, urinary frequency, upper respiratory infection, pharyngitis, sinusitis, cough, headache, fatigue, asthenia, fever, edema, back pain, weight increase, and diplopia. Common side effects include nausea, anorexia, vomiting, hemiparesis, dizziness, poor coordination, amnesia, insomnia, paresthesia, somnolence, paresis, ataxia, anxiety, dysphagia, depression, confusion, rash, and pruritus.

temozolomide

Temodal® Oncology An alkylating agent used for recurrent gliomas–eg, anaplastic astrocytoma, and possibly melanoma and other solid tumors. See Astrocytoma, Glioblastoma multiforme.
References in periodicals archive ?
Temozolomide is the routinely used radiosensitizer during radiotherapy and chemotherapy cycles and has shown good results.
By 1997, clinical trials have shown the drug could bring significant benefits to people with brain tumours Partnering with CRUK, the University of Strathclyde was able to manufacture and supply temozolomide in capsules to treat patients in CTs.
Novocure announced that a detailed quality of life analysis of Novocure's EF-14 phase 3 pivotal trial of Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma has been published in JAMA Oncology.
Standard treatment includes surgery to remove as much of the tumor as is safely possible, followed by radiation therapy and chemotherapy with temozolomide.
This fast track status applies to two ongoing clinical trials sponsored by DelMar Pharmaceuticals to evaluate VAL-083 as a potential treatment for rGBM, including a Phase 2 study in bevacizumab-naAaAaAeA ve MGMT-unmethylat GBM patients conducted in collaboration with The University of Texas MD Anderson Cancer Center, and a Phase 3 study of patients whose disease has progressed following prior treatment with temozolomide and bevacizumab (the STAR-3 trial).
First, temozolomide has been the most common agent chosen as a systemic therapy regimen because it is believed to penetrate the blood-brain barrier.
The aim of the phase Ib trial will be to determine the safety of the experimental drug, PAC-1, when used in combination with the standard brain-cancer chemotherapy drug, temozolomide.
CT-179, projected to enter the clinic in the first half of 2018, has been shown to significantly prolong survival in relevant animal models, especially when combined with the standard of care treatments, temozolomide and radiation therapy.
Given our recent $9 million financing, we have the resources to facilitate the initiation of our pivotal Phase III study of VAL-083 as a single agent treatment for GBM patients who have failed both temozolomide (Temodar) and bevacizumab (Avastin), for whom there is no currently approved therapy.
To explore, researchers from the Institute of Psychiatry at King's College London used mice to study the effects of temozolomide, the standard chemotherapy for brain cancer.
Temozolomide (TMZ) has been used with irradiation (IR) to treat gliomas.